Relationship between labile plasma iron, liver iron concentration and cardiac response in a deferasirox monotherapy trial

Haematologica

Volumn 96, Issue 7, 2011, Pages 1055-1058

  Wood, John C ^a   Glynos, Tara ^b   Thompson, Alexis ^c   Giardina, Patricia ^d   Harmatz, Paul ^e   Kang, Barinder P ^b   Paley, Carole ^b   Coates, Thomas D ^a  

^a CHILDREN S HOSPITAL LOS ANGELES   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c CHILDREN'S MEMORIAL HOSPITAL   (United States)

^d WEILL CORNELL MEDICAL CENTER   (United States)

^e CHILDREN S HOSPITAL OAKLAND   (United States)

Author keywords

Cardiac T2*; Chelation; Deferasirox; Heart; Labile plasma iron; MRI; Non transferrin bound iron; Siderosis; Thalassemia

Indexed keywords

DEFERASIROX; IRON;

ARTICLE; CARDIOVASCULAR RESPONSE; CLINICAL ARTICLE; DISEASE SEVERITY; DRUG TREATMENT FAILURE; HEMOSIDEROSIS; HUMAN; IRON BLOOD LEVEL; LIVER LEVEL; MONOTHERAPY; MULTICENTER STUDY; OPEN STUDY; PREDICTION; TREATMENT DURATION; TREATMENT RESPONSE;

BENZOIC ACIDS; BETA-THALASSEMIA; FERRITINS; HEART; HUMANS; IRON; IRON CHELATING AGENTS; IRON OVERLOAD; LIVER; MYOCARDIUM; PROGNOSIS; TREATMENT OUTCOME; TRIAZOLES;

EID: 79959945510     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2010.032862     Document Type: Article

References (19)

1. Oudit GY, Trivieri MG, Khaper N, Liu PP, Backx PH. Role of L-type Ca2+ channels in iron transport and iron-overload cardiomyopathy. J Mol Med. 2006;84(5):349-64.
2. Esposito BP, Breuer W, Sirankapracha P, Pootrakul P, Hershko C, Cabantchik ZI. Labile plasma iron in iron overload: redox activity and susceptibility to chelation. Blood. 2003;102(7):2670-7.
3. Zanninelli G, Breuer W, Cabantchik ZI. Daily labile plasma iron as an indicator of chelator activity in Thalassaemia major patients. Br J Haematol. 2009;147(5):744-51.
4. Ghoti H, Fibach E, Merkel D, Perez-Avraham G, Grisariu S, Rachmilewitz EA. Changes in parameters of oxidative stress and free iron biomarkers during treatment with deferasirox in iron-overloaded patients with myelodysplastic syndromes. Haematologica. 2010;95(8):1433-4.
5. Cabantchik ZI, Breuer W, Zanninelli G, Cianciulli P. LPI-labile plasma iron in iron overload. Best Pract Res Clin Haematol. 2005;18(2):277-87.
6. Koren A, Fink D, Admoni O, Tennenbaum-Rakover Y, Levin C. Non-transferrin-bound labile plasma iron and iron overload in sickle-cell disease: a comparative study between sickle-cell disease and beta-tha lassemic patients. Eur J Haematol. 2010;84 (1):72-8.
7. Daar S, Pathare A, Nick H, Kriemler-Krahn U, Hmissi A, Habr D, et al. Reduction in labile plasma iron during treatment with deferasirox, a once-daily oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia. Eur J Haematol. 2009;82 (6):454-7.
8. Wood JC, Kang BP, Thompson A, Giardina P, Harmatz P, Glynos T, et al. The effect of deferasirox on cardiac iron in thalassemia major: impact of total body iron stores. Blood. 2010;116(4):537-43.
9. Piga A, Longo F, Duca L, Roggero S, Vinciguerra T, Calabrese R, et al. High nontransferrin bound iron levels and heart disease in thalassemia major. Am J Hematol. 2009;84(1):29-33.
10. Angelucci E, Brittenham GM, McLaren CE, Ripalti M, Baronciani D, Giardini C, et al. Hepatic iron concentration and total body iron stores in thalassemia major. N Engl J Med. 2000;343(5):327-31.
11. Brittenham GM, Griffith PM, Nienhuis AW, McLaren CE, Young NS, Tucker EE, et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med. 1994;331(9):567-73.
12. Jensen PD, Jensen FT, Christensen T, Eiskjaer H, Baandrup U, Nielsen JL. Evaluation of myocardial iron by magnetic resonance imaging during iron chelation therapy with deferrioxamine: indication of close relation between myocardial iron content and chelatable iron pool. Blood. 2003;101(11):4632-9.
13. Telfer PT, Prestcott E, Holden S, Walker M, Hoffbrand AV, Wonke B. Hepatic iron concentration combined with long-term monitoring of serum ferritin to predict complications of iron overload in thalassaemia major. Br J Haematol. 2000;110(4):971-7.
14. Jacobs EM, Hendriks JC, van Tits BL, Evans PJ, Breuer W, Liu DY, et al. Results of an international round robin for the quantification of serum non-transferrin-bound iron: Need for defining standardization and a clinically relevant isoform. Anal Biochem. 2005;341(2):241-50.
15. Angelucci E, Muretto P, Nicolucci A, Baronciani D, Erer B, Gaziev J, et al. Effects of iron overload and hepatitis C virus positivity in determining progression of liver fibrosis in thalassemia following bone marrow transplantation. Blood. 2002;100(1):17-21.
16. Olivieri NF, Nathan DG, MacMillan JH, Wayne AS, Liu PP, McGee A, et al. Survival in medically treated patients with homozygous beta-thalassemia. N Engl J Med. 1994; 331(9):574-8.
17. Noetzli LJ, Carson SM, Nord AS, Coates TD, Wood JC. Longitudinal analysis of heart and liver iron in thalassemia major. Blood. 2008;112(7):2973-8.
18. Anderson LJ, Westwood MA, Prescott E, Walker JM, Pennell DJ, Wonke B. Development of thalassaemic iron overload cardiomyopathy despite low liver iron levels and meticulous compliance to desferrioxamine. Acta Haematol. 2006;115(1-2):106-8.
19. Gabutti V, Piga A. Results of long-term iron-chelating therapy. Acta Haematol. 1996;95(1):26-36.